Latest

2 stories

Hide weekly roundups

Yesterday

Quarterly updateKura Oncology, Inc.Tango Therapeutics, Inc.

Tango reports pancreatic cancer combo data, plans Phase 3 start in 1H 2027

Tango Therapeutics said its vopimetostat-daraxonrasib combination hit an 82% response rate in pancreatic cancer and reported $977.5 million in cash as of September 30, 2026.

SEC filing (2)

Wednesday, September 9

FinancingKura Oncology, Inc.

Kura Oncology spins out Caspian Therapeutics for cardiometabolic menin inhibitors

Kura formed Caspian Therapeutics as a subsidiary, contributed menin inhibitor assets including KO-7246, and Caspian raised $50 million in a Series A financing.

SEC filing